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Sirolimus-eluting stents versus standard stents in patients with stenosis
in a native coronary artery
Moses JW, Leon NB, Pomma JJ, et al. N Engl J Med 2003;349:1315-23.
Conclusion: Sirolimus-eluting stents in patients with complex coro-
nary artery disease reduced the rate of recurrent stenosis and related clinical
events in all subjects analyzed, including patients with diabetes, patients with
longer coronary lesions, and patients with small coronary arteries.
Summary: Sirolimus (Rapamycin) is a cytostatic lactone with antipro-
liferative and anti-inflammatory properties. When delivered via a polymer-
encapsulated stent it reduces risk for restenosis in patients undergoing
coronary artery stenting who are at low risk for restenosis. In this study the
authors investigated the utility of Sirolimus-eluding stents in patients with
more complex coronary lesions at greater risk for restenosis.
This was a randomized double-blind clinical trial comparing Sirolimus-
eluting stents with standard stents in 1058 patients. Fifty-three centers in the
United States were used. All patients had a newly diagnosed lesion in a native
coronary artery. Twenty-six percent of the patients included in this study had
diabetes, many had longer coronary artery lesions (mean, 14.4 mm), and
many had small vessels (mean, 2.8 mm). The primary end point was failure
of the target vessel within 270 days after stent implantation. Failure was
defined as death from cardiac causes, Q-wave or non-Q-wave myocardial
infarction, or revascularization of the target vessel with either open coronary
surgery or repeat coronary angioplasty.
Target vessel failure was reduced from 21% with the standard stent to
8.6% with Sirolimus-eluting stents (P  .001). This end point was driven
largely by the decreased frequency of target vessel revascularization in
patients with the drug-eluting stents (16.6% in the standard stent group vs
4.1% in the Sirolimus stent group; P  .001). Results in favor of the
Sirolimus-eluting stent held for all subgroups, including the patients with
diabetes, those with smaller vessels, and those with more complex coronary
lesions. Three-hundred fifty patients in the Sirolimus stent group and 353 in
the standard stent group had angiographic follow up. The frequency of
in-stent restenosis of at least 50% lumen diameter was 35.4% in the standard
stent group and 3.2% in the Sirolimus stent group (P  .001).
Comment: The study indicates a consistent and powerful treatment
effect of Sirolimus-eluting stents in patients with complex coronary lesions
out to 270 days. Longer follow-up is clearly required. Short-term benefits do
not always translate into long-term benefits.
Evaluation of D-dimer and the diagnosis of suspected deep vein throm-
bosis
Wells PS, Anderson DR, Rodger M, et al. N Engl J Med 2003;349:1227-35.
Conclusion: The combination of a D-dimer assay and a clinical predic-
tion model of the possibility of deep venous thrombosis (DVT) can safely
reduce the number of ultrasound examinations required in the evaluation of
patients with possible DVT.
Summary: D-dimer fragments are produced during degradation of
fibrin clots, and suggest the presence of thrombosis. Different assays vary in
their sensitivity for detection of D-dimer and in their ease of use and expense.
It is postulated that D-dimer assays with high negative predictive values for
DVT may be useful in the evaluation of patients with possible DVT, perhaps
permitting avoidance of ultrasound testing in some patients with a negative
assay. It has also been shown that a clinical probability scoring system can be
used, along with a single negative ultrasound examination, to rule out DVT
in patients whose probability score suggests a low likelihood of DVT.
Outpatients with suspected lower extremity DVT were categorized as
likely or unlikely to have DVT. Patients were then randomly assigned to
undergo ultrasonography alone (control group, n 530) or D-dimer testing
(D-dimer group, n 569) followed by ultrasonography, unless the D-dimer
test was negative and the patients’ clinical probability scores suggested they
were unlikely to have DVT. In these cases duplex scanning for DVT was not
performed. D-dimer testing was performed with the SimpliRED assay (Agen
Biomedical) or IL test (Instrumentation Laboratory).
The prevalence of DVT was 15.7%. In patients in whom DVT was ruled
out with the initial diagnostic strategy, over the next 3 months there were two
confirmed venous embolic events in the D-dimer group (0.4%) and six in the
control group (1.4%; P .16). D-dimer testing lowered the use of ultrasonog-
raphy from a mean of 1.34 tests per patient in the control group to a mean of
0.78 tests per patient in the D-dimer group (P .008). Thirty-nine percent of
patients in the D-dimer group did not require ultrasound imaging.
Comment: This study indicates that it is possible to safely omit venous
ultrasound studies in highly selected patients with a low probability of DVT.
Implementation of this protocol may allow vascular laboratories to reduce
after-hours venous duplex studies and to improve working conditions and
retention of vascular technologists.
Vascular access outcomes using the transposed basilic vein arterio-
venous fistula
Segal JH, Kayler LK, Henke P, et al. Am J Kidney Dis 2003;42:151-157.
Conclusion: Patency rates for transposed basilic vein arteriovenous fistulas
(TBAVF) are not so good as those initially reported in smaller studies.
Summary: The authors performed an analysis of TBAVFs to determine
patency rates and risk factors for primary failure. This was a retrospective analysis
of 99 patients who had TBAVFs created for hemodialysis access between April
1997 and October 2001. In 46% of the patients this was the initial access.
Patient mean age was 55 years, and 46% were male. Primary patency rates for
TBAVFs at 1 and 2 years were 47% and 41%, and assisted patency rates were 64%
and 58%, respectively. In 23% of cases there was primary failure of the TBAVF.
Unassisted access patency was worse in patients who had a previous access
(relative risk [RR], 2.04; 95% confidence interval [CI], 1.09-3.85; P .03) and
in patients who had an ipsilateral central venous catheter (RR, 2.92; 95% CI,
1.34-6.38; P  .01). Primary access failure was increased by the presence of
older age (RR, 2.0), obesity (RR, 7.1), and previous dialysis access (RR, 6.4).
Steal syndrome necessitating intervention occurred in 5% of cases.
Comment: This study represents the largest single-center evaluation of
TBAVFs for dialysis access. The reported results are similar to those reported in
a comparison of prosthetic grafts, autogenous fistulas, and venous transpositions
from the United States Renal Data System Dialysis Morbidity and Mortality
Study published in The Journal in 2001. The current results, however, are
inferior to some studies reporting unassisted patency rates as high as 90% in 1
year (Hakaim AG, et al, J Vasc Surg 1998;27:154-7). Given the results of
national data, it is likely the authors’ assisted and unassisted patency rates are
reflective of what will be achieved in most centers with the use of TBAVFs for
dialysis access. This paper is important in that it highlights certain patient groups
that may not receive substantial benefit over prosthetic grafts with the use of
TBAVFs. It suggests the need for a multicenter prospective randomized trial
evaluating the efficacy of TBAVFs versus prosthetic grafts in patients who are
older, obese, or have had previous vascular access.
Collagen- versus gelatin-coated Dacron versus stretch PTFE bifurca-
tion grafts for aortoiliac occlusive disease: Long-term results of a
prospective, randomized multicenter trial
Preager MR, Hoblaj T, Nanobashbili J, et al. Surgery 2003;134: 80-5.
Conclusion: There are no patency differences when knitted, gelatin-
coated Dacron, knitted collagen-coated Dacron, and stretch polytetrafluo-
roethylene (PTFE) aortic grafts are compared for the treatment of aortoiliac
occlusive disease.
Summary: This was a randomized multicenter trial at three tertiary
referral centers, comparing the patency of knitted, gelatin-coated Dacron,
knitted collagen-coated Dacron, and stretch PTFE aortic bifurcation grafts.
Fifty-two patients received the gelatin-coated Dacron graft, 49 patients the
collagen-coated Dacron graft, and 48 patients the PTFE graft. Thirty-day
operative mortality was 4%. No intraoperative deaths occurred. Mean fol-
low-up was 97 months.
At 8 years, primary patency for the knitted gelatin-coated Dacron grafts
was 77%, primary patency for the collegen-coated Dacron grafts was 78%,
and primary patency for the PTFE grafts was 79% (P .8). There was also no
significant difference in secondary 8-year patency rates (91%, gelatin-coated
Dacron grafts; 96%, collagen-coated Dacron grafts; and 90%, PTFE grafts;
P  .5). None of the patients in this study were thought to have hypoplastic
aortic syndrome, and none needed grafts smaller than 14/7 mm. Overall
there were six graft infections, five in Dacron grafts and one in a PTFE graft.
Four percent of grafts became infected during follow-up.
Comment: Statistically there was no difference between the Dacron
and PTFE grafts (P  .05) in terms of infection. The trend, however, is
worrisome, and further studies evaluating relative infection rates of Dacron
and PTFE grafts in the aortic position seem warranted. The authors’
conclusion that the three graft materials do not differ in terms of long-term
patency, complications, or risks for infection seems warranted. However, a
type II error may be masking a difference in relative infection rates between
Dacron and PTFE grafts.
Cerebral hemodynamics in asymptomatic and symptomatic patients
with high-grade carotid stenosis undergoing carotid endarterectomy
Soinne L, Helenius J, Tatlisumak T, et al. Stroke 2003;34:1655-61
Conclusion: Hemodynamic adaption to high-grade carotid stenosis is
inferior in patients with symptomatic carotid stenosis compared with those
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with asymptomatic carotid stenosis, and there are differences in the cerebral
hemodynamic response to carotid endarterectomy (CEA) in patients with
symptomatic and asymptomatic carotid stenosis.
Summary: The authors used dynamic susceptibility contrast magnetic
resonance imaging (DSC-MRI ) and transcranial Doppler scanning tech-
niques to investigate hemodynamic changes in cerebral perfusion induced by
carotid stenosis and how they were affected by CEA. In addition, they
sought to determine whether there were differences between patients with
asymptomatic and symptomatic carotid stenosis. Finally, they examined
differences between gray and white matter, and watershed regions with
respect to these hemodynamic changes.
Twenty three patients with asymptomatic high-grade unilateral carotid
stenosis and 23 patients with symptomatic high-grade unilateral carotid
stenosis were examined with DSC-MRI and transcranial Doppler ultrasound
scanning before CEA and subsequently 3 and 100 days after CEA. Patients
with symptomatic carotid stenosis, in comparison with patients with asymp-
tomatic carotid stenosis, had increased preoperative transit time of the MRI
contrast bolus and lower cerebral blood flow values in the hemisphere
ipsilateral to the high-grade carotid stenosis. These flow abnormalities were
more pronounced in white matter and watershed regions than in gray matter
regions. Asymmetric flow patterns between hemispheres were abolished
with CEA. Improvements over time were greater in patients with symptom-
atic carotid stenosis. With regard to changes with transcranial Doppler
scanning, a breath-holding index, a measure of cerebrovascular reactivity,
improved in the symptomatic carotid stenosis patients after CEA. There was
no change in the asymptomatic patients after CEA.
Comment: The improved ability of patients with asymptomatic carotid
stenosis to hemodynamically adapt to the high-grade carotid lesion may
partially account for a lesser benefit of surgery in patients with asymptomatic
carotid disease.
Kissing stents for treatment of complex aortoiliac disease
Greiner A, Dessl A, Klein-Weigel P, et al. Eur J Vasc Endovasc Surg 2003;
26:161-5.
Conclusions: Technical and short term clinical success for kissing stents in
the treatment of aortoiliac occlusive disease is acceptable. Patency beyond 18
months is inferior to that associated with bypass surgery. Kissing stents should
be reserved for patients at high risk, with limited life expectancy.
Summary: This was a retrospective study to determine technical and
clinical success of the kissing stent technique for treatment of aortoiliac occlusive
disease. Twenty-five patients with either critical limb ischemia or intermittent
claudication secondary to aortoiliac occlusive disease were studied. Forty-one
iliac arteries were described as having “complex stenoses and 8 occluded.” The
procedures were performed via bilateral retrograde femoral artery punctures,
and used either balloon or self-expanding stents. Technical success was defined
as restoration of patency with less than 30% residual diameter stenosis, and
clinical success was defined as improvement in walking distance or improvement
of two Fontaine categories of critical limb ischemia. Patients were followed up
with duplex scanning, and greater than 50% luminal reduction was defined as
peak systolic velocity greater than 230 cm/s. Angiography during follow-up was
performed only when the patient was considered for repeat intervention. A
successful hemodynamic response to stenting was defined as an ankle-brachial
index (ABI) greater than 0.9 in the presence of essentially normal runoff or an
increase in ABI of 0.15 in cases of impaired runoff. The patients were followed
up with physical examination, ABI, exercise testing, and duplex scanning at 1, 3,
6, and 12 months, and then yearly.
Technical success was obtained in 86% of arterial segments treated.
Three puncture site pseudoaneurysms required surgery, and the 30-day
mortality rate was 0%. There were no major amputations within 30 days.
There were two late amputations associated with progression of distal
disease, and seven late deaths. Three follow-up interventions and one
thrombectomy for restenosis were required at a mean of 15.9 9.4 months.
The primary assisted patency rate for the iliac limbs was 94%, 91%, and 65%
at 6, 12, and 24 months, respectively.
Comment: The kissing stent technique has become popular for treat-
ment of complex aortoiliac occlusive disease associated with stenoses, pri-
marily at the level of the aortic bifurcation. Clearly, the 65% 24-month
patency of the iliac limbs is disappointing. However, with the exception of
repair of groin pseudoaneurysms, patients were apparently not harmed by
the procedure, and most stents were patent after 2 years. Depending on
one’s perspective, the data in this article can be used to support the initial use
of catheter-based techniques for treatment of complex aortoiliac occlusive
disease or to support the use of initial bypass surgery in patients who are
appropriate surgical candidates.
Comparison of low-intensity warfarin therapy with conventional-in-
tensity warfarin therapy for long-term prevention of recurrent venous
thromboembolism
Kearon C, Ginsberg JS, Kovacs MJ, and the Extended Low-Intensity
Anticoagulation for Thromboembolism Investigators. N Engl J Med 2003;
349:631-9.
Conclusion: Extended conventional-intensity wafarin therapy (CIWT;
international normalized ratio [INR] 2.0-3.0), compared with extended
low-intensity warfarin therapy (LIWT; INR 1.5-1.9), provides improved
protection against recurrent venous throboembolism (VTE) at no increased
risk for bleeding.
Summary: The authors previously determined that patients with idio-
pathic venous thrombosis had a decreased incidence of recurrent VTE if
warfarin therapy was continued for 2 years rather than discontinued after 3
months. No patient had recurrent VTE with extended warfarin therapy
(INR 2.0-3.0). However, overall therapeutic efficacy was limited by in-
creased bleeding. In this study the authors performed a randomized, double-
blind study in patients with VTE to compare extended warfarin therapy with
an INR target of 1.5-1.9 (low intensity) to extended warfarin therapy with
an INR target of 2.0-3.0 (conventional intensity).
Seven hundred thirty-eight patients treated for 3 months or longer with
warfarin because of idiopathetic VTE were randomized to receive either
continued CIWT or continued LIWT . Average follow-up was 2.4 years.
Three hundred sixty-nine patients were assigned to LIWT, and 16 had
recurrent VTE (1.9 per 100 person-years). Of 369 patients assigned to
CIWT, 6 had recurrent VTE (0.7 per 100 person-years). The hazard ratio
for recurrent VTE with extended LIWT versus extended CIWT was 2.8
(95% confidence interval [CI], 1.1-7.0).
Major bleeding was defined as clinically overt bleeding associated with
a hemoglobin decrease of 2.0 g/dL, need for transfusion of two or more
units of red blood cells, or bleeding that involved critical sites such as the
retroperitoneum or intracranium. There was a major bleeding incidence of
1.1 events per 100 person-years in the LIWT group and 0.9 events per 100
person-years in the CIWT group. The hazard ratio for major bleeding with
LIWT versus CIWT prolonged warfarin therapy was 1.2 (95% CI, 0.4-3.0).
There was also no significant difference in the frequency of overall bleeding
between the two groups.
Comment: Unprovoked VTE is defined as VTE occurring without an
obvious transient risk factor, such as surgery or trauma. Patients may have an
underlying coagulation disorder, and in this study 35% of the patients had
either a factor V Leiden abnormality or an abnormality in the prothrombin
gene. The data strongly indicate that prolonged warfarin therapy for patients
with unprovoked VTE clearly reduces the risk for recurrent VTE. Overall,
LIWT given after 3 months of CIWT reduces subsequent VTE by approx-
imately 75%. Prolonged CIWT reduces the subsequent risk for recurrent
VTE by 90%. For patients without prohibitive risk factors for bleeding and
with unprovoked VTE, prolonged warfarin therapy is clearly indicated.
Inhibition of clinical benefits of aspirin on first myocardial infarction
by nonsteroidal anti-inflammatory drugs
Kruth T, Glynn RJ, Walker AN, et al. Circulation 2003;108:1191-5.
Conclusion: There may be an increased rate of myocardial infarction
(MI) in apparently healthy male physicians taking prophylactic aspirin therapy
who also use nonsteroidal anti-inflammatory agents (NSAIDs) on a regular
basis, compared with those taking aspirin therapy with less use of NSAIDs.
Regular use of NSAIDs not specific to the cyclooxygenase-2 (COX-2) coen-
zyme may impede the beneficial cardiovascular effects of aspirin.
Summary: This is a subgroup analysis of the Physician’s Health Study
(PHS). In the PHS, 23,071 apparently healthy male physicians between 40
and 84 years of age at entry and without a history of cardiovascular disease or
other major illness were randomized to receive either 325 mg of aspirin every
other day, -carotene every day, both active agents, or both placebos. The
study was stopped in January 1998, because of the emergence of a significant
beneficial effect of aspirin on the development of first myocardial infarction.
Aspirin provided a 44% risk reduction in myocardial infarction in the
participants in the study (P  .00001).
Aspirin is thought to prevent ischemic events by irreversible inhibition
of cyclooxygenase-1 (COX-1). NSAIDs exert their effects primarily by
inhibition of COX-2 and subsequent reduced prostaglandin production.
Many NSAIDs, however, also inhibit COX-1. Aspirin and NSAIDs share a
common binding site on COX-1. NSAIDs may compete for binding sites
with aspirin on the COX-1 isoenzyme, raising the possibility that NSAIDs
may obviate the beneficial cardiovascular effects of aspirin.
In the PHS, data were recorded on NSAID use. In this subgroup analysis
the authors found that participants in the PHS who used NSAIDs from 1 to 59
days per year did not have an increased risk for MI (relative risk [RR], 1.21; 95%
confidence interval [CI], 0.78-1.87). However, participants in the study who
were randomized to aspirin and who used NSAIDs more than 60 days per year
had an increased relative risk for first MI, compared with those who did not use
NSAIDs (RR, 2.86; 95% CI, 1.25-6.56).
Comment: Post hoc analysis such as that presented in this study
provides the basis and rationale for design of proper prospective trials. Post
hoc analyses should not be regarded as definitive studies. The authors are
correct in urging caution in interpreting the implications of their data.
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